Actinogen Medical share price crashes 67% lower on Alzheimer's study results

The Actinogen Medical Ltd (ASX:ACW) share price has been one of the worst performers on the ASX with a 67% decline today. Here's why…

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

One of the worst performers on the Australian share market on Tuesday has been the Actinogen Medical Ltd (ASX: ACW) share price.

In morning trade the Alzheimer's-focused drug development company's shares are down 67% to 1.6 cents.

Why has the Actinogen Medical share price crashed lower today?

Investors have been hitting the sell button this morning after Actinogen Medical released the results of its XanADu phase II clinical trial of 10mg Xanamem in patients with mild dementia due to Alzheimer's disease.

According to the release, the XanADu trial established that a 10mg daily dose of Xanamem is safe and has the ability to effectively inhibit cortisol production, as demonstrated by the expected increase in related hormones, including adrenocorticotropic hormone (ACTH).

However, it did not demonstrate adequate efficacy in improving cognition in mild Alzheimer's disease. Disappointingly, the primary and secondary endpoint measures did not demonstrate statistical differences between Xanamem 10mg and placebo.

What now?

It isn't necessarily the end of the road just yet. Management advised that further analysis of the trial data is underway in the hope of exploring trends that could identify any specific cognitive domains in which positive trends may be evident.

It also suggested that higher doses of Xanamem and longer treatment durations may be necessary to effectively demonstrate its potential to improve cognition in Alzheimer's disease.

Studies using 20mg and 30mg doses are underway and results are expected to be announced by the end of June. After which, management will use the data to refine Xanamem's ongoing clinical development program.

Despite the disappointing results, the company's CEO, Dr Bill Ketelbey, was encouraged by the trial.

He said: "These XanADu results are certainly encouraging. While 10mg Xanamem was not shown to be a clinically effective dose in Alzheimer's disease, the safety and pharmacodynamic effects observed show potential that higher doses and a longer treatment duration of Xanamem may be efficacious."

Also in the news today in the pharmaceutical industry is Mayne Pharma Group Ltd (ASX: MYX). The Mayne Pharma share price has dropped 1% lower after analysts at UBS held firm with their neutral rating but cut the price target on its shares to 73 cents after revising down margins for its generics segment.

Elsewhere, the CSL Limited (ASX: CSL) share price has pushed 1% higher despite there being no news out of the biotech giant.

James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Fallers

A woman with a sad face looks to be receiving bad news on her phone as she holds it in her hands and looks down at it.
Share Fallers

Why Fisher & Paykel Healthcare, Humm, Novonix, and Webjet shares are tumbling today

These shares are having a tough session on Thursday. What's going on? Let's find out.

Read more »

a man weraing a suit sits nervously at his laptop computer biting into his clenched hand with nerves, and perhaps fear.
Share Fallers

This ASX All Ords stock just crashed 23%! Here's why

Investors are sending the ASX All Ords stock tumbling today. But why?

Read more »

A young woman holds an open book over her head with a round mouthed expression as if to say oops as she looks at her computer screen in a home office setting with a plant on the desk and shelves of books in the background.
Share Fallers

Why GQG, Novonix, Silex, and Vulcan Energy shares are sinking today

These shares are having a tough time on hump day. But why?

Read more »

A woman faces the camera with her lip raised up to the side in total confusion.
Bank Shares

Why is the CBA share price being hit so hard today?

Has CBA's luck finally run out?

Read more »

A young man clasps his hand to his head with his eyes closed and a pained expression on his face as he clasps a laptop computer in front of him, seemingly learning of bad news or a poor investment.
Share Fallers

Why ASX, CBA, Iperionx, and Sayona Mining shares are dropping today

These shares aren't having a good session on Tuesday. But why?

Read more »

A businesswoman exhales a deep sigh after receiving bad news, and gets on with it.
Share Fallers

Why Bell Financial, IPD, Megaport, and Resolute Mining shares are falling today

These shares are starting the week in the red. But why?

Read more »

A male investor wearing a blue shirt looks off to the side with a miffed look on his face as the share price declines.
Share Fallers

Why Megaport, Pilbara Minerals, Vysarn, and WiseTech shares are falling today

These shares are ending the week in the red. But why?

Read more »

A young man clasps his hand to his head with his eyes closed and a pained expression on his face as he clasps a laptop computer in front of him, seemingly learning of bad news or a poor investment.
Share Fallers

Why Accent, Sayona Mining, Web Travel, and Weebit Nano shares are dropping today

These shares are having a tough time on Thursday. Why are they being sold off?

Read more »